The purpose of this study is to examine the effect of smoking cessation medications on alcohol drinking. Effect of 2mg/day, 1mg/day, placebo varenicline was evaluated. Following 7 days of medication pre-treatment to achieve steady state levels, participants complete a laboratory session assessing alcohol self-administration behavior. Study enrolls heavy drinking smokers (not tested under nicotine deprivation), non-daily smokers, and nonsmokers. Volunteers are administered either varenicline (Chantix) or placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
2mg/day or 1mg/day with 1-week medication lead-in period.
placebo
Yale Center for Clinical Investigation and Yale Behavioral Pharmacology Laboratory
New Haven, Connecticut, United States
Number of Drinks Consumed
number of drinks consumed during hour 1 and hour 2 of the 120 minute alcohol self-administration session
Time frame: 2 hour ad-lib drinking period, during the laboratory session (Day 8)
Alcohol Craving
alcohol craving during the alcohol priming dose period using a visual analog scale of alcohol craving (1-100; higher scores = higher craving)
Time frame: during laboratory session (Day 8) at baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.